
TOTAL N = 2626
Paliperidone ER studies, n =1697
Risperidone studies, n = 929
Excluded:
Excluded doses, active comparators*, n = 1040
No conventional antipsychotic ≤90 days, n = 653
N = 933
Paliperidone ER studies, n = 434
Risperidone studies, n = 499
Propensity score matched
N = 575
Paliperidone ER
6-12 mg/day
n = 179
Risperidone
2-4 mg/day
n = 113†
Risperidone
4-6 mg/day
n = 129†
Placebo (PALI)
n = 95
Placebo (RIS)
n = 122
Completed: 64.8%
Discontinued
•Lack of efficacy: 17.3%
•Withdrew consent: 8.4%
•Adverse event: 6.7%
•Lost to follow up: 0.6%
•Noncompliance: 0.6%
•Other: 1.7%
Completed: 54.0%
Discontinued
•Lack of efficacy: 23.9%
•Withdrew consent: 12.4%
•Adverse event: 6.2%
•Lost to follow up: 0.9%
•Noncompliance: 2.7%
•Other: 0
Completed: 66.7%
Discontinued
•Lack of efficacy: 10.9%
•Withdrew consent: 9.3%
•Adverse event: 8.5%
•Lost to follow up: 1.6%
•Noncompliance: 2.3%
•Other: 0.8%
Completed: 36.8%
Discontinued
•Lack of efficacy: 43.2%
•Withdrew consent: 10.5%
•Adverse event: 5.3%
•Lost to follow up: 2.1%
•Noncompliance: 0
•Other: 2.1%
Completed: 51.6%
Discontinued
•Lack of efficacy: 29.5%
•Withdrew consent: 1.6%
•Adverse event: 4.9%
•Lost to follow up: 1.6%
•Noncompliance: 4.9%
•Other: 2.5%